Abstract: Few antibiotic options exist for the management of infections due to vancomycin-resistant enterococci. We describe a case involving the safe and successful use of tedizolid, a new oxazolidinone, to treat vancomycin-resistant enterococci prosthetic joint infection.
1,2 Furthermore, vancomycin resistance is present in up to 79% of Enterococcus faecium isolates. 2 Currently, one antibiotic, linezolid, an oxazolidinone, is approved by the US Food and Drug Administration for the treatment of infections due to VRE. Tedizolid, a next-generation oxazolidinone currently Food and Drug Administration approved for acute bacterial skin and skin structure infections, including those caused by Enterococcus faecalis but not E. faecium, exhibits broad-spectrum activity against the majority of Gram-positive organisms, including VRE. Here, we present a case describing the novel, unlabeled use of tedizolid for a prolonged period (4 weeks) to treat a prosthetic joint infection (PJI) due to vancomycinresistant E. faecium.
CASE REPORT
A 51-year-old woman with a history of total right hip arthroplasty (THA) 17 months ago, complicated by recurrent PJI, presented with rhabdomyolysis after 2 weeks of treatment with daptomycin. After her initial right total right hip arthroplasty, she had developed recurrent PJI due to a number of different organisms, requiring explantation of her prosthesis, 5 subsequent surgical incision and debridements, and multiple courses of antimicrobial therapy (Fig. 1) . Intraoperative cultures were positive for several pathogens: vancomycin-sensitive E. faecalis, coagulase-negative staphylococci, and Pseudomonas aeruginosa. However, intraoperative cultures collected from the patient's acetabulum and hip fascia during the most recent debridement yielded coagulase-negative staphylococci and vancomycin-resistant E. faecium, susceptible to daptomycin, linezolid, doxycycline, and quinupristin-dalfopristin (Table 1) . Gram stain performed on these specimens did not reveal any polymorphonuclear leukocytes or microorganisms. Daptomycin was started 2 weeks before her presentation with a significant reduction in the pain and swelling of her affected hip. Unfortunately, she developed severe pain in both forearms and was diagnosed with rhabdomyolysis with a peak serum creatine kinase level of greater than 28,000 U/L. Daptomycin was promptly discontinued and her rhabdomyolysis resolved.
In light of the susceptibility of the isolated E. faecium to linezolid, the patient was started on tedizolid 200 mg by mouth once daily. Her psychiatric history was notable for major depression and anxiety, for which she was prescribed venlafaxine, amitriptyline, and doxepin. These were discontinued as a precaution upon discussion with her primary care physician before receiving tedizolid. The patient was continued on ciprofloxacin to treat the previously isolated P. aeruginosa. In total, the patient was treated with tedizolid in an inpatient setting for 28 days with significant clinical improvement in her PJI and a reduction in her serum C-reactive protein from 35.1 mg/L (before the start of daptomycin) to 4.1 mg/L at discharge. At no point did she manifest symptoms of serotonin syndrome or treatment-related thrombocytopenia. At 4-month follow-up after discontinuation of tedizolid, she had no clinical signs of relapse of VRE PJI and has not received chronic suppressive antibiotic therapy. A joint aspiration was not performed after completion of treatment with tedizolid.
DISCUSSION
This case demonstrates the successful use of tedizolid to treat vancomycin-resistant E. faecium PJI. Although enterococci are responsible for only a small fraction (approximately 3%-10%) of PJIs, the emergence of VRE presents a significant therapeutic challenge. 3, 4 Tedizolid is an attractive candidate for the treatment of VRE, surpassing linezolid for several reasons. In vitro, tedizolid may be a more potent drug, with several-fold lower minimum inhibitory concentrations (MICs) against VRE than linezolid. 5 Furthermore, tedizolid seems to retain activity against linezolid-and daptomycin-resistant enterococci, displaying MIC values on average 4-to 8-fold lower compared with linezolid. 6 Commercial methods for antimicrobial susceptibility testing of tedizolid are not routinely available, and there are no interpretive criteria for defining susceptibility in E. faecium. In this case, susceptibility of the VRE to tedizolid was inferred from the isolate's susceptibility to linezolid, because linezolid susceptibility has been shown to be highly predictive of tedizolid susceptibility. In 1 study, 99.8% of enterococcal isolates that were susceptible to linezolid were also susceptible to tedizolid. 7 Finally, tedizolid may be better tolerated than linezolid, with several studies suggesting a significantly lower risk of serotonin syndrome and thrombocytopenia compared with linezolid. [8] [9] [10] Little is known regarding the use or efficacy of tedizolid in the treatment of PJI. No studies have investigated the penetration of tedizolid into synovial fluid or bone to date. The effectiveness of tedizolid against staphylococci isolated from PJIs was assayed in 1 study. 11 All isolates of Staphylococcus aureus and Staphylococcus epidermidis were susceptible to tedizolid in a planktonic state, but against isolates in a biofilm state, MICs for tedizolid were approximately 1 to 2 dilutions higher. This pattern was similarly observed for vancomycin as well. Yet, the clinical improvement of our patient may be evidence that tedizolid reaches adequate killing concentrations in bone and synovium.
Specific guidelines do not exist for the optimal management of PJI caused by VRE, although daptomycin and linezolid are often used and are recommended for the treatment of PJI due to penicillin-resistant enterococci. 12 Tedizolid should be considered as an alternative agent to treat VRE PJI in the setting of antibiotic resistance, medication intolerance, or potential drug-drug interactions.
CONCLUSIONS
Our case describes the novel, successful, and unlabeled use of tedizolid in the treatment of PJI secondary to vancomycinresistant E. faecium. The safe, extended duration (4 weeks) of treatment suggests that tedizolid can be used for managing infections requiring prolonged therapy such as PJI, with the potential for less hematological toxicity and risk of interaction with serotonergic agents compared with linezolid. Further research is warranted to better characterize the clinical efficacy of tedizolid against VRE in PJI and other osteoarticular infections. 
